Triazolothiadiazole inhibitor of c-met protein kinase

Abstract

The present invention relates to compound 1, which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising Compound 1 and methods of using the compositions in the treatment of proliferative disorders.

1 . A compound having the formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The compound of  claim 1 , wherein said compound is crystalline. 
     
     
         3 . The compound of  claim 2 , wherein said compound is characterized by one or more of the following peaks in an X-ray diffraction pattern: 6.3, 9.2, 11.5, 13.3, 13.8, 14.2, 14.8, 16.2, 18.2, 18.7, and 19.8. 
     
     
         4 . A pharmaceutical composition comprising the compound according to  claim 1  or  2 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle. 
     
     
         5 . The composition according to  claim 4 , additionally comprising a chemotherapeutic or anti-proliferative agent, an anti-inflammatory agent, an agent for treating atherosclerosis, or an agent for treating lung fibrosis. 
     
     
         6 - 9 . (canceled)